<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072785</url>
  </required_header>
  <id_info>
    <org_study_id>LUYESIKE-VSL-Ⅲ-01</org_study_id>
    <nct_id>NCT02072785</nct_id>
  </id_info>
  <brief_title>Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia</brief_title>
  <acronym>LY01609</acronym>
  <official_title>Phase III Study of Vincristine Sulfate Liposome Or Vincristine Sulfate For Injection Combined Chemotherapy as Initial Induction Regimen In Adults Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Luye Sike Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ethics Committee of Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanjing Luye Sike Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether vincristine sulfate liposome could reduce
      less peripheral neuropathy than vincristine sulfate,and be as effective as vincristine
      sulfate in adults with Naïve Acute Lymphoblastic Leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate(objectives (ORR)</measure>
    <time_frame>up to 35 days</time_frame>
    <description>ORR=CR+CRi CR(Complete response)
No circulating blasts or extramedullary disease, No lymphadenopathy,splenomegaly,skin/gum infiltration/testicular mass/CNS involvement
Trilineage hematopoiesis(TLH)and &lt;5% blast in bone marrow
ANC&gt;1000/microl
Platelets&gt;100,000/microl
CRi(Complete response with incomplete recovery of counts) Recovery of platelets but&lt;100,000 or ANC is &lt;1000/microl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of General peripheral neuropathy</measure>
    <time_frame>A week before enrollment. one,two,three and four weeks after the start of induction chemotherapy</time_frame>
    <description>Chemotherapy-induced peripheral neuropathy was evaluated By Total Neuropathy Score clinical Version(TNSc).
If the score of any item of TNSc at anytime after the start of induction chemotherapy is higher than the baseline,it is considered that peripheral neuropathy occurs.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Adult Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Vincristine Sulfate Liposome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vincristine Sulfate For Injection simulation agent 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection: 1.4mg/m2, (2mg, maximum dose), iv, d1, d8, d15, d22.
Duration between these two agents should be more than 2.5h, and saline should be avoided for flushing before Vincristine Sulfate Liposome For Injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vincristine Sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vincristine Sulfate For Injection 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection simulation agent: 1.4mg/m2,(2mg, maximum dose), iv, d1, 8, 15, 22.
Duration between these two agents should be more than 2.5h, and saline should not be used for flushing before Vincristine Sulfate Liposome For Injection simulation agent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate Liposome</intervention_name>
    <arm_group_label>Vincristine Sulfate Liposome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <arm_group_label>Vincristine Sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  De novo untreated ALL patients diagnosed by the bone marrow morphology,
             immunophenotype.

          -  65 ≥ Age (years) ≥ 18 , male or female,

          -  ECOG Performance status of 0, 1, or 2.

          -  Patients must fulfill the following laboratory values

               1. Total bilirubin ≤2 ULN (corrected for same age)

               2. AST and ALT ≤3 ULN ( corrected for same ages)

               3. Serum creatinine ≤2 ULN (corrected for same age)

          -  Didn't receive any of the following treatments within 4 weeks before inclusion:
             chemotherapy, radiotherapy, replacement therapy, operation, long term of
             glucocorticoid therapy（&gt;5 days）.

          -  No neurological disorders, no nerve or muscle injury (motor and sensory nerve).

          -  Patient must sign the informed consent and obey the protocol.

        Exclusion Criteria:

          -  Atopy or allergic to multiple medicines or excipients.

          -  With serious complications that affect compliance.

          -  Serious organ dysfunctions or central nervous system disorders.

          -  Mixed phenotype acute leukemia, (T-B).

          -  Burkitt lymphoma/leukemia.

          -  Suspected or confirmed central nervous system leukemia.

          -  Diabetes.

          -  Received antifungal treatment with triazole agents within 1 month before inclusion.

          -  Reliance of antipyretic and analgesic medicines or psychotropic medicines.

          -  Undergoing or has undergone other clinical trials in 4 weeks before inclusion.

          -  Pregnant women, women of breast feeding or childbearing potential without
             contraception.

          -  Psychological disorders that affect signing consent.

          -  The investigators believe that patients who are not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yingchang Mi, Doctor</last_name>
    <phone>86-10-22-23909999</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of Blood Diseases, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingchang MI, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult Acute Lymphoblastic Leukemia</keyword>
  <keyword>Vincristine Sulfate Liposome</keyword>
  <keyword>Vincristine Sulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

